Analytical Data
-
Gene name
SLFN12L
- Application
-
Alternative Names
SLFN12L; SLFN5Schlafen family member 12-like
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6IEE8
-
Expression Region
1-588aa
-
Molecular Weight
72.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLFN12L (Schlafen 12-like) is a member of the Schlafen family of proteins, which are known to play significant roles in immune regulation and differentiation processes. The study of SLFN12L has gained attention due to its potential implications in various biological pathways, including cell cycle regulation and antiviral responses. Recent research indicates that SLFN12L may influence T cell activation and proliferation, possibly by modulating translational control of specific mRNAs. This is particularly relevant in the context of viral infections and cancer, where immune response modulation can significantly impact disease outcomes. Understanding the mechanisms by which SLFN12L exerts its effects on immune cells could lead to novel therapeutic approaches for enhancing immune responses or developing targeted treatments for immune-related disorders. Additionally, the reconstitution of SLFN12L as a recombinant protein allows for detailed structural and functional analyses, paving the way for elucidating its role in cellular processes and interactions with other molecular partners. This research aims to unravel the complex network of SLFN12L functions, providing insights into its potential as a biomarker or therapeutic target in immunological research and clinical applications.
